Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose vs Standard-Dose Fluzone in Elderly
NCT00115531Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Apr 2005
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of Fluzone Trivalent in influenza, sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Reactogenicity at 7 days and Immunogenicity. Started Apr 2005; status: completed.
02
Drugs
Fluzone Trivalent
03
Conditions
influenza
Beyond the preview
Go deeper on NCT00115531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115531.